Tag - Mycapssa

Markets

Brookline starts Chiasma at buy; PT $15

Brookline Capital Markets initiated coverage of Chiasma (NASDAQ:CHMA) with a “buy” rating and $15 price target. Chiasma is developing Mycapssa as potential maintenance treatment for adults with acromegaly, a hormonal...

July 25, 2019

Developments

Chiasma’s Mycapssa meets all endpoints in Phase 3 acromegaly trial

Chiasma (NASDAQ:CHMA) reported positive top-line Phase 3 data from a pivotal trial evaluating its octreotide candidate, conditionally trade-named Mycapssa, for the treatment of acromegaly. Acromegaly is caused by the...

July 23, 2019

Tag - Mycapssa

Brookline starts Chiasma at buy; PT $15

Chiasma’s Mycapssa meets all endpoints in Phase 3 acromegaly trial

General

More